Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
Hi David- I’M feeling a bit overwhelmed as I have gone the natural route and thought I had things under control but my MM came back just as my onc. said it would. Not sure what way to turn now.
The treatment plan they are proposing looks awful. They would be using Revlimid this time along with immunotherapy and two steroids and other drugs for side effects. Last thing I wanna do to my body but afraid I will give him because of fear.
As I have an aggressive form it spreads very quickly so don’t have too much time to figure things out.
I’m considering heavy dose Cannabis for a few months after speaking to a woman in Vancouver who had healed her own cancer plus many others and is very well-known.
Very expensive though and not too much money to play with. Any ideas would be greatly appreciated. Lucy
” Herein, we also found that the CBD and THC combination is able to reduce expression of the β5i subunit as well as to act in synergy with CFZ to increase MM cell death and inhibits cell migration. In summary, these results proved that this combination exerts strong anti-myeloma activities…”
“Results: The response rates (above VGPR) were 74.1% and 32.8% in the ABCD- and BD-treated groups, respectively (P = 0.000). Compared to BD regimen, ABCD regimen significantly improved PFS (P = 0.026) and OS (P = 0.000) in newly diagnosed patients.
Patients with a high tumor burden, low or standard risk, and without auto-HSCT seemed to especially benefit compared to the same group with BD regimen. ABCD also showed better tolerability with lower bone marrow suppression (P = 0.026). Furthermore, complete response or near CR after induction therapy was a good prognostic factor for ABCD-associated OS and PFS.
Conclusion: ABCD is an effective and tolerable regimen compared with BD regimen in newly diagnosed myeloma patients. ABCD regimen could be an economical, effective, and tolerable choice in low- and standard-risk patients.”